Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to compare the best overall response rate
(BORR)(as per modified WHO criteria) in patients with previously treated, therapy-refractory,
or -intolerant, Stage III (unresectable) or Stage IV melanoma receiving ipilimumab doses of
0.3, 3, and 10 mg/kg. The safety of this product will also be evaluated.